Pay in 4 interest-free payments of $5.13 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status
Peptide Sciences+1 NNMT is a cytosolic enzyme that catalyzes methyl transfer from S-adenosyl methionine (SAM) to nicotinamide and related substrates
Are B12 Shots Better Than Pills
These findings revealed that GLP-1 is not merely a glucose-regulating hormone but a key player in the complex neuroendocrine network that governs food intake and body weight
